156 related articles for article (PubMed ID: 15242368)
1. Dexamethasone and interleukin-2 combination therapy for advanced renal cell carcinoma in a patient with paraneoplastic inflammatory syndrome.
Shinojima T; Oya M; Kohno H; Marumo K; Murai M
Int J Urol; 2004 Jul; 11(7):553-6. PubMed ID: 15242368
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II study of thalidomide in combination with interleukin-2 in patients with metastatic renal cell carcinoma.
Amato RJ; Morgan M; Rawat A
Cancer; 2006 Apr; 106(7):1498-506. PubMed ID: 16475152
[TBL] [Abstract][Full Text] [Related]
3. Progressive anemia following combination therapy with interferon-alpha and interleukin-2 in a patient with metastatic renal cell carcinoma.
Hosokawa Y; Kishino T; Ono T; Oyama N; Hayashi K; Momose H
Int J Urol; 2004 Oct; 11(10):906-8. PubMed ID: 15479299
[TBL] [Abstract][Full Text] [Related]
4. [Successful treatment for renal cell carcinoma with lung metastases by interleukin-2 and interferon-alfa: a case report].
Sakata Y; Ogura Y; Wakita T; Hayashi N; Sugimura Y
Hinyokika Kiyo; 2003 Jul; 49(7):389-91. PubMed ID: 12968479
[TBL] [Abstract][Full Text] [Related]
5. [Synergetic responses after administration of interleukin-2 and Interferon-alpha combined with gamma knife radiosurgery in a patient with multiple lung and brain metastases: a case report].
Takada T; Yamada Y; Uno M; Komeda H; Fujimoto Y
Hinyokika Kiyo; 2005 Jun; 51(6):381-4. PubMed ID: 16050476
[TBL] [Abstract][Full Text] [Related]
6. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
Amato RJ; Malya R; Rawat A
Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant interleukin-2, interferon-alpha, and 5-fluorouracil immunochemotherapy after radical nephrectomy for locally advanced renal cell carcinoma.
Hong SK; Kwak C; Lee SE
Urology; 2005 Sep; 66(3):518-22. PubMed ID: 16140069
[TBL] [Abstract][Full Text] [Related]
9. [Etiopathogenesis and management of paraneoplastic fever and Stauffer syndrome in renal carcinoma].
Muñoz Vélez D; Rebasa Llull M; Hidalgo Pardo F; Riera Marí V; Mus Malleu A; Gutiérrez Sanz-Gadea C; Ozonas Moragues M
Actas Urol Esp; 1999 Apr; 23(4):379-83. PubMed ID: 10394662
[TBL] [Abstract][Full Text] [Related]
10. Ukrain treatment in a patient with metastatic renal cell carcinoma extending to the vena cava inferior. Case report.
Prokopchuk OL; Zemskov SV; Susak YM
Drugs Exp Clin Res; 2000; 26(5-6):257-9. PubMed ID: 11345035
[TBL] [Abstract][Full Text] [Related]
11. Bullous pemphigoid is a rare paraneoplastic syndrome in patients with renal cell carcinoma.
Klein T; Rotterdam S; Noldus J; Hinkel A
Scand J Urol Nephrol; 2009; 43(4):334-6. PubMed ID: 19308806
[TBL] [Abstract][Full Text] [Related]
12. Outpatient treatment with subcutaneous interleukin-2, interferon alpha and fluorouracil in patients with metastatic renal cancer: an Australian experience.
Marx G; Taylor J; Goldstein D
Intern Med J; 2005 Jan; 35(1):34-8. PubMed ID: 15667466
[TBL] [Abstract][Full Text] [Related]
13. [Use of interleukine-2 in a patient with renal cancer and paraneoplastic vasculitis].
Demidov LV; Semenkova EN; Kharkevich GIu; Timofeev IV
Ter Arkh; 2004; 76(10):23-5. PubMed ID: 15575472
[No Abstract] [Full Text] [Related]
14. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
Culine S; Iborra F; Mottet N; Avancès C; de Graeve B; Volpé P; Vignoud J; Bringer JP; Marroncle M; Le Pellec L; Ayuso D; Jansen E; Faix A; Rebillard X
Am J Clin Oncol; 2006 Apr; 29(2):148-52. PubMed ID: 16601433
[TBL] [Abstract][Full Text] [Related]
15. Benign mucous membrane pemphigoid of the upper aero-digestive tract: rare paraneoplastic syndrome presentation in renal cell carcinoma.
Saravanan K; Baer ST; Meredith A; Dyson A; von der Werth J
J Laryngol Otol; 2006 Mar; 120(3):237-9. PubMed ID: 16549040
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
[TBL] [Abstract][Full Text] [Related]
17. Delirium after interleukin-2 and alpha-interferon therapy for renal cell carcinoma.
van Steijn JH; Nieboer P; Hospers GA; de Vries EG; Mulder NH
Anticancer Res; 2001; 21(5):3699-700. PubMed ID: 11848546
[TBL] [Abstract][Full Text] [Related]
18. "Late" regressions of metastases from renal cancer after a period of disease progression continuing the same intermittent low dose immunotherapy regimen.
Giacosa R; Santi R; Vaglio A; Pavone L; Ferrozzi F; Passalacqua R; Buzio C
Acta Biomed; 2004 Aug; 75(2):126-30. PubMed ID: 15481703
[TBL] [Abstract][Full Text] [Related]
19. Stauffer's syndrome with jaundice, a paraneoplastic manifestation of renal cell carcinoma: a case report.
Tomadoni A; García C; Márquez M; Ayala JC; Prado F
Arch Esp Urol; 2010 Mar; 63(2):154-6. PubMed ID: 20378939
[TBL] [Abstract][Full Text] [Related]
20. Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.
Pacheco AV; Rasila K; Lee SJ; Rabinowitz I; Elias L; Lee FC; Verschraegen CF
Urol Oncol; 2008; 26(6):610-5. PubMed ID: 18367103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
